Pfizer advances Litfulo for vitiligo in face of Incyte and AbbVie competition on July 30, 2026 AbbVie Incyte Janus kinase inhibitor LITFULO Opzelura Pfizer Phase 3 regulatory filings Rinvoq Ritlecitinib Vitiligo +
AbbVie Scores First Rinvoq Alopecia Nod in EU on July 29, 2026 AbbVie Alopecia Approved CHMP Commission EU European (ethnic group) Janus kinase inhibitor Phase 3 Rinvoq SALT score Severe (severity modifier) systemic treatment UP-AA +
Incyte Scores Phase 3 Wins for Povorcitinib in Vitiligo Treatment on April 29, 2026 Approved Incyte Janus kinase inhibitor Phase 3 povorcitinib STOP-V1 STOP-V2 ) United States Food and Drug Administration Vitiligo +